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Abstract
An effective vaccine prioritization process is essential to prevent the many issues that
currently weaken global vaccination efforts. Identifying challenges associated with vaccine
development is important when considering which initiatives will provide immunization that is
effective, affordable, and easy to administer. The process of establishing priorities for vaccine
development is complicated, though, by the conflicting interests of multiple stakeholders
involved in the vaccine market. Additionally, uncertainties exist regarding: (1) the resources and
time required for vaccine development, (2) the expected benefits of development, and (3) the
anticipated demand for vaccination, further complicating the prioritization process.
This study proposes a decision-support tool for prioritizing vaccine initiatives through the
use of mathematical optimization models. The tool will allow a panel of decision makers to
assess vaccine candidates over multiple criteria with information that is both quantitative and
qualitative. This assessment will be the result of a methodology that integrates Data
Envelopment Analysis and the Analytic Hierarchy Process. Ultimately, the decision-support tool
will allow researchers and funding agencies to determine which vaccine initiatives should be:
more effective, affordable, profitable, reliable, easier to use and store, and more suitable to the
needs of multiple populations from diverse locations and having multiple logistic needs.

1. Introduction
With numerous vaccine initiatives in various stages of development around the world,
government funding agencies, foundations, vaccine producers, and researchers are faced with the
challenge of determining which initiatives should be fostered and receive additional attention and
financial support. For these organizations, a renewed focus on developing priority-setting
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strategies for new vaccine development is timely and critical. This is evident in the 2010
National Vaccine Plan, a report by the U.S. government with goals for enhancing all aspects of
vaccines and vaccination. In the report, strategies are listed to guide disease prevention and
improve vaccination, including: “develop and implement a process for prioritizing and
evaluating new vaccine targets of domestic and global public health importance” [1]. The
Institute of Medicine (IOM) has also targeted vaccine prioritization as an integral part in the
design of a national and global vaccine development strategy. Despite a few efforts by the IOM
to address the vaccine prioritization problem, to date, no universally accepted method or model
exists to guide these important decisions [2].
Prioritizing vaccine initiatives can provide a framework for organizations or stakeholders
in the vaccine market to discuss investment alternatives and converge toward solutions that
satisfy most parties. Additionally, allocating proper resources to a vaccine initiative can reduce
the time it spends in development, allowing it to provide immunization to the public sooner.
Increased interests, efforts, and collaborations related to vaccine-preventable diseases are adding
to the need for vaccine prioritization. Figure 1 shows the market attractiveness of vaccine
investments over the last 30 years. A renewed interest in vaccine development is evident, with a
number of organizations and foundations focusing on the advancement of new vaccines.
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Figure 1: Historical attractiveness of vaccine investments.
SOURCE: Institute of Medicine, 2012 [2].

For any organization choosing to invest in the development of a vaccine initiative, there
are a number of factors that make the decision to select one project over another challenging.
Varying public health environments, social and economic infrastructures, political conditions,
and climates, for example, can have a significant impact on the effectiveness and profitability of
an initiative. These circumstances can vary significantly around the world and can heavily
influence a vaccine initiative’s likelihood of success. Additionally, decision makers can face
uncertainty regarding: the expected length of time for the vaccine to become licensed for use, the
vaccine initiative’s financial viability, and the logistic challenges associated with vaccine
delivery. Other aspects that influence vaccine prioritization include: the magnitude of disease
burden, public perception of the disease and the need for its control, whether the disease has the
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potential to cause epidemics and pandemics, whether the vaccine has characteristics that are
attractive for use in developing countries, and the cost-effectiveness of the vaccine [3].
Key stakeholders of the vaccine market assess the importance of vaccine criteria
differently, and while organizations’ internal mechanisms to set priorities are not well known or
publicized, information has been gathered about the varying priorities of the public sector,
private sector, and non-governmental groups. Manufacturers, for example, favor the
development of vaccines that promise high returns and involve the use of currently available
technologies. Non-governmental organizations such as UNICEF, GAVI, and PAHO, on the
other hand, are interested in expanding immunization in developing countries and developing
vaccines that are inexpensive, easy to distribute, and do not require the use of expensive cold
chains. Furthermore, different governments (from developing and industrialized nations) are
interested in the development of vaccines that target diseases specific to their regions.
An effective vaccine prioritization process will bring together government agencies,
vaccine manufacturers, humanitarian groups, and other organizations invested in the
development of vaccines, allowing them to collectively identify vaccine priorities that best
represent everyone’s interests or provide the least level of conflict. In this thesis, the
development of an optimization based heuristic is proposed that considers the interests of
multiple stakeholders to prioritize vaccine candidates that are at different developmental stages
and target different diseases. Moreover, a heterogeneous group of decision makers is assumed
with different interests and levels of expertise. Therefore, vaccine prioritization is addressed as a
multiple criteria decision making (MCDM) problem, involving multiple decision makers who
base their decisions on both quantitative and qualitative information. The next section describes
previous attempts at prioritizing vaccine initiatives.
4

2. Previous Vaccine Prioritization Efforts
The Institute of Medicine, aware of the difficulty associated with vaccine prioritization,
established three committees over the last 30 years to address the vaccine prioritization problem.
In 1985, the Institute of Medicine (IOM) published its first report on vaccine prioritization:
“New Vaccine Development: Establishing Priorities: Volume 1, Diseases of Importance in the
United States” [4]. Part one of a two-part study, this report aimed to help the National Institute of
Allergy and Infectious Diseases (NIAID) establish priorities for accelerated vaccine
development. The committee behind the report was charged with developing a decision-making
framework to prioritize vaccine candidates for the US population. In addition, the committee was
asked to evaluate the model’s ability to set priorities for vaccines needed by technologically less
developed nations, and modify the model to rank potential vaccines for international use. The
committee’s findings relative to the international aspects of vaccine development appeared in
part two of the study: “New Vaccine Development: Establishing Priorities: Volume 2, Diseases
of Importance in Developing Countries” [5].
The method used by the committee to rank vaccine initiatives was based on a quantitative
model in which vaccine candidates were ranked according to two criteria: (1) expected health
benefits measured by the reduction of morbidity and mortality, and (2) expected net savings of
health care resources. A measurement system based on infant mortality equivalents (IMEs) 1 was
used to compare the health impacts of a disease versus the potential benefits of a vaccine.
Estimates and judgments by experts were also used when information was incomplete. The

1
death.

The number of acute morbidity days or chronic cases considered to be equal in undesirability to an infant
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committee adopted a flexible format so that new candidate vaccines could be assessed similarly
or current candidate vaccines could be reassessed with new data.
Since the time the report was published, analytical techniques have advanced and other
metrics have proven to be better measures of health valuation. In addition, the epidemiological
data used to compare diseases was variable in quality and in some cases, completely absent. This
created a serious impediment to the development of a comprehensive prioritization scheme,
leading the IOM to create a second committee in 2000 to address the same problem.
The 2000 report, “Vaccines for the 21st Century” [6], used an efficiency measure for
deriving its priorities based on the incremental cost per incremental quality adjusted life year
gained by vaccination ($/QALY). Using this measure, initiatives were grouped into one of four
categories. The highest priority, Level I, was designated for vaccine programs projected to save
money and increase the number of QALYs. Vaccine programs that did not save money were
grouped into the remaining three categories based on the efficiency of the investment. Level II
included candidates whose $/QALY was less than $10,000, Level III included candidates for
which $/QALY ranged between $10,000 and $100,000, and Level IV was for candidates whose
$/QALY was greater than $100,000.
Like the 1985-1986 IOM model, one weakness of the 2000 IOM model was that it only
considered a single attribute to propose vaccine priorities. Additionally, the 2000 model did not
provide a method for choosing between vaccine initiatives with equal QALYs when one targeted
a minor form of illness affecting a large portion of the population, and the other targeted a
disease with a small number of cases but high mortality and the potential for large social
disruption. An additional shortcoming of the 2000 model was that it only focused on vaccine
candidates for the US market.
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The IOM’s most recent attempt at addressing the vaccine prioritization problem is
currently in development and is the focus of the report: “Ranking Vaccines: A Prioritization
Framework: Phase I: Demonstration of Concept and a Software Blueprint” [2]. For this recent
modeling strategy, the committee limited its scope to models that consider multiple attributes;
the committee recognized that the narrow range of attributes used to prioritize vaccines in the
previous IOM studies significantly limited their value and applications. The three multi-attribute
approaches that the committee reviewed were: mathematical programming, multi-attribute utility
theory, and the analytic hierarchy process. These approaches were evaluated against four criteria:
transparency, axiomatic foundation, priority scaling, and sensitivity analysis. Ultimately, multiattribute utility theory was chosen for the foundation of the committee's work because it provides
weights and data that are available for all users to see and use, independence from irrelevant
alternatives (IIA), scaling that can be used for an ordinal ranking, and the ability to conduct
sensitivity analyses on results [2].
The current committee's model improves upon the previous two by including multiple
attributes that address the varied interests of the public sector, private sector, and nongovernmental groups. However, as mentioned in the “2010 National Vaccine Plan” [1],
collaboration between stakeholders is an important part of establishing and understanding
priorities for development. This is a major weakness of the new model, which rather than
promote collaboration, allows users to create priorities that result solely from the application of
their own criteria or interests. The fact that the model only considers a single decision maker’s
preferences ignores the idea that vaccine prioritization should reflect the perspectives of multiple
stakeholders. Therefore, despite the IOM's efforts, there is still a need for a prioritization model
that considers the individual interests of stakeholders but also encourages collaboration between
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them. The prioritization model, in accompaniment with stakeholder input, should be able to
generate a vaccine ranking that best addresses the conflicting interests of all stakeholders. This is
the focus of the model proposed in the following section.

3. Methodology
3.1 Overview
The overall goal of this project is to develop a mathematical optimization model that
derives a vaccine priority ranking using quantitative and qualitative criteria and the preferences
of multiple stakeholders. The model is designed to complement the IOM’s current prioritization
effort. The proposed algorithmic methodology integrates Data Envelopment Analysis (DEA)
with the Analytic Hierarchy Process (AHP). This method has each individual in a panel of
decision makers compare: the qualifications of their peers for assessing vaccine initiatives, how
well each criteria satisfies the goal, and how well each initiative performs with respect to each
criteria. Pairwise comparison matrices for the decision makers, criteria of evaluation, and
initiatives with respect to each criterion are derived using the AHP framework. DEA is then used
to calculate the optimal weight of each decision maker, the optimal weight of each criteria of
evaluation, and the optimal weight of each initiative with respect to each criteria of evaluation.
The optimal weights are then used to calculate the relative priority of each initiative.
3.2 AHP
Developed by Saaty in the 1970s, the Analytic Hierarchy Process (AHP) helps decision
makers identify alternatives that best suit their interests [7]. The ranking/selection of a set of
alternatives is done with respect to an overall goal, which is broken down into a set of criteria.
Figure 1 shows the basic hierarchical structure of an AHP problem.
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Figure 2: AHP hierarchical structure

The AHP provides a comprehensive and rational framework for representing and
quantifying the elements of decision problems, relating those elements to overall goals, and
evaluating alternative solutions. Applying the AHP to a decision problem involves four steps: 1)
structuring the problem into a hierarchical model, 2) comparing elements of the problem to one
another to generate pairwise comparison matrices, 3) calculating the weight or priority of each
element in the hierarchy, and 4) aggregating the weights across various levels to obtain the final
weights of the alternatives. (See [8].)
Pairwise comparison matrices are an integral part of the AHP, indicating how much more
important one objective might be than another. Let

A=

=[

]

(1)

be a pairwise comparison matrix for a single decision maker. The entry in row i and column j of
A indicates how much more important objective i is than objective j, with
1/

= 1 for all i and

=

for j ≠ i. How to calculate priorities from a pairwise comparison matrix has been the focus

of several studies, with techniques aimed at deriving a priority vector including: the eigenvector
method [9], the weighted least-square method (WLSM) [10], the logarithmic least square method
(LLSM) [11], and the fuzzy programming method [12].
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3.3 DEAHP
In 2006, Ramanathan [13] developed a method that uses data envelopment analysis
(DEA) for generating local weights of alternatives from pairwise comparison matrices in the
AHP. DEA is a linear programming based approach used to determine the productive efficiency
of a system or decision-making-unit (DMU) (e.g., a university, hospital, or restaurant) by
comparing how well the DMU converts inputs into outputs. The DMU that produces the largest
amount of outputs by consuming the least amount of inputs is considered to have an efficiency
score of one. The efficiencies of the other DMUs are obtained relative to the efficient DMU, and
are assigned efficiency scores between zero and one [8]. Ramanathan’s method, referred to as
DEAHP, considers each criterion or alternative in a pairwise comparison matrix as a DMU. The
row elements of the pairwise comparison matrix are viewed as the outputs of the DMUs, and a
dummy input with a value of one is used to build a model that calculates the efficiency score for
each DMU. The efficiency scores are then used as the local priorities of the DMUs, whether they
are decision criteria or alternatives.
The DEAHP method succeeds in producing true weights for perfectly consistent pairwise
comparison matrices, but was criticized by Wang et al [14] for not being able to produce rational
weights for inconsistent pairwise comparison matrices. In addition, Wang et al [14] proved that
the DEAHP may also produce illogical results for pairwise comparison matrices with satisfactory
consistency. As a result, Wang and Chin [15] introduced a new DEA methodology in 2009.
3.4 DEA Methodology for Priority Determination in the Group AHP
Wang and Chin’s DEA methodology [15] is aimed at deriving the best local priority
vector from a pairwise comparison matrix or, for the group AHP, the best local priority vectors

10

from a group of pairwise comparison matrices, regardless of whether they are perfectly
consistent or inconsistent.
Let
=[

=

]

(2)

be a pairwise comparison matrix provided by the kth decision maker (DMk) (k = 1,…, m),
where

is the kth decision maker’s assessment of how important objective i is relative to

objective j, and m is the number of decision makers. In addition, let hk > 0 be the decision
maker’s relative importance weight satisfying ∑

, and

,…,

be the decision

variables. The following model is solved for each wi (i = 1,…,n) to obtain the best relative local
priorities of the n criteria or alternatives under group decision making. Subscript zero represents
the decision criterion or alternative under evaluation, namely DMU 0:
=∑

Maximize
∑
Subject to {∑

∑

∑

(3)

∑

∑

After the best local priorities for both criteria and alternatives have been derived by the
DEA methodology, the final weight of each decision alternative can be computed using the
simple additive weighting (SAW) method [9]. Let
decision criteria and

, …,

, …,

be the best local priorities of the m

be the best local priorities of the n decision alternatives with

respect to the jth criterion (j = 1,…, m). Equation (4) can be used to calculate the final weight of
each decision alternative.
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Final weight of Alternative

= ∑

(4)

The above methodology is effective in assessing the value of different alternatives, given
the assignment of the decision maker weights is correct. Decision maker weights are a)
determined by an outside decision maker, or b) agreed upon by the decision makers involved in
the decision making process. For certain group decision making problems, though, there might
not be any individuals outside of the problem who are qualified to assign decision maker
weights, or if a group decision making problem is highly classified, having an outside decision
maker assign decision maker weights is not an option. When decision makers must work
together to identify their weights, they must discuss their qualifications for making the decision
with each other. This can be an impractical and even inconvenient conversation to have,
especially when members of the group have to identify who among them is least qualified to
address the problem. A method for calculating decision maker weights using the members of the
group in an anonymous manner is essential to preserving the integrity of the group decision
making process.
We propose to adapt the DEA methodology proposed by Wang and Chin [15] to address
the vaccine prioritization problem. To do this, we will expand Wang and Chin’s model for group
decision making to calculate not only the local priorities of the criteria and alternatives, but also
the weights of the decision makers, whose inputs will be used to provide feedback about
stakeholder preferences and priorities. The following section reviews the proposed methodology.
3.5 Comprehensive DEA Methodology for Priority Determination in the Group AHP
Consider a problem where d decision makers must establish the relative priority of p
projects or initiatives, while considering their performance over c different attributes or criteria.
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Let

=[

=

]

be a pairwise comparison matrix provided by the kth decision maker

(5)

) (k = 1,…, d), where

is the kth decision maker’s assessment of how qualified decision maker i is relative to
decision maker j for assessing the given problem. The linear programming model in (6) is solved
for each

(i = 1,…,d) to obtain the weights of the d decision makers involved in group decision

making:
Maximize

=∑
∑

Subject to {∑

For the model (6),

∑
∑

(6)
∑

∑

is the relative weight or score for decision maker i and

is the

score of decision maker j with respect to decision maker i. In addition, h is the initial weight of
each decision maker and is equal to 1/d. The first constraint requires the sum of the output values
with respect to each decision maker to equal one. The second constraint is a product of Saaty’s
eigenvector method [9].
Next, let

=

=[

]

be a pairwise comparison matrix provided by the kth decision maker where

(7)

is the kth

decision maker’s assessment of how important criteria i is relative to criteria j in satisfying the
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goal. The linear programming model in (8) is solved for each CRi (i = 1,…,c) to obtain the
weights of the c criteria related to the given problem:
=∑

Maximize

∑
Subject to {∑

For the model (8),

∑
∑

(8)
∑

∑

is the relative weight or score for criterion i and

criterion j with respect to criterion i. In addition,

is the score of

is the weight of each decision maker as

calculated by model (6). The first constraint requires the sum of the output values with respect to
each criterion to equal one. The second constraint is a product of Saaty’s eigenvector method [9].
Now, let

=[

=

]

(9)

be a pairwise comparison matrix provided by the kth decision maker where

is the kth

decision maker’s assessment of how project i compares to project j with respect to criteria l. The
linear programming model in (10) is solved for each PCRil (i = 1,…,p. l = 1,…,c.) to obtain the
weight of each project with respect to the each criteria:
Maximize

=∑
∑

Subject to {∑

∑
∑

,

(10)

∑

∑
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For the model (10),
criterion l and

is the relative weight or score for project i with respect to

is the score of project j with respect to criterion l with respect to the project-

criterion being evaluated (project i with respect to criterion l). In addition,

is the weight of

each decision maker as calculated by model (6). The first constraint requires the sum of the
output values with respect to each project-criterion to equal one. The second constraint is a
product of Saaty’s eigenvector method [9].
Lastly, the final weight of each initiative can be computed using the simple additive
weighting (SAW) method [9]. Let
criteria and

, …,

, …,

be the best local priorities of the c decision

be the best local priorities of the i decision alternatives with respect

to the lth criterion (l = 1,…, c). Equation (4) can be used to calculate the final weight of each
decision alternative.
Final weight of Alternative

= ∑

(11)

3.6 Arrow’s Impossibility Theorem
According to Arrow’s impossibility theorem [16], when voters have three or more
distinct alternatives, no rank order voting system can convert the ranked preferences of
individuals into a community-wide ranking while also meeting the following criteria:
-

If every voter prefers alternative A to alternative B, then the group prefers A to B.

-

If every voter prefers alternative A to alternative B, then any change in preferences that
does not affect this relationship must not affect the group preference for A over B. This
requirement is also known as “independence from irrelevant alternatives” (IIA).
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-

There are no dictators; no single voter possesses the power to always determine the
group’s preference.

The Comprehensive DEA Methodology for Priority Determination in the Group AHP
(CDEAGAHP) is a rank-order system that was designed to satisfy the first two criteria while
allowing decision makers to have different weights of influence over the decision-making
process. If every voter prefers alternative A to alternative B, then the group ranking will have
alternative A ranked above alternative B. If an alternative is eliminated from consideration, then
the new ordering for the remaining alternatives will be equivalent to the original ordering minus
the eliminated alternative (IIA). Lastly, the CDEAGAHP allows a decision maker to have more
weight than other decision makers by applying the AHP and DEA to derive weights based on
peer evaluations.
An illustrative example that demonstrates an application of the Comprehensive DEA
Methodology for Priority Determination in the Group AHP (CDEAGAHP) is explained in
Appendix A. The following section applies the methodology to a vaccine prioritization problem.

4. Vaccine Prioritization Using the Comprehensive DEA Methodology for
Priority Determination in the Group AHP
Data was gathered to apply the Comprehensive DEA Methodology for Priority
Determination in the Group AHP (CDEAGAHP) to a vaccine prioritization problem with five
decision makers evaluating ten vaccine candidates against ten criteria. For the five decision
makers, two were chosen to represent the interests of the public sector, two were chosen to
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represent the interests of the private sector, and one was chosen to represent the interests of nongovernmental organizations. These decision makers are listed in Table 10.
Table 10: Vaccine Example Decision Makers
Decision Maker

Sector

Health Agency Representative

Pubic

Public Health Unit Representative

Public

Vaccine Industry Representative

Private

Biopharmaceutical Industry Representative

Private

International Vaccine Initiative Representative

Non-governmental Organization

Ten criteria were chosen for the experiment that are similar to some of the 29 criteria
used in the 2012 IOM model. Criteria were chosen to capture the health, economic,
demographic, scientific, business, and programmatic considerations associated with vaccine
development. The ten criteria are listed in Table 11.

Table 11: Vaccine Example Criteria
Criterion

Definition

Target Population

Vaccine targets a disease that affects a
population of interest

Cost-Effectiveness

$/QALY gained

Incident Cases Prevented Per Year Through

The number of incident cases of disease

Vaccination

prevented in one year

Total Development Costs

Sum of development costs
17

Potential to Improve Delivery Methods

Vaccine development has the potential to
improve delivery methods or stimulate novel
approaches to deliver vaccines

Premature Deaths Averted Per Year Through

The number of deaths due to disease

Vaccination

prevented in one year

QALYs Gained

Net increase in QALYs gained in the
population vaccinated

Reduces Challenges Relating to Cold Chain

Vaccine development has the potential to

Requirements

stimulate novel approaches to mitigate the
challenges relating to cold-chain storage and
related packaging.

Healthcare Cost Reduction

Health care costs saved

Time to Licensure

The estimated length of time until successful
licensure

For the vaccine candidates, ten were chosen as a subset of the 26 vaccine candidates that
were used for evaluation in “Vaccines for the 21st Century” [6]. The ten vaccine candidates are:
‘Chlamydia’, ‘Group A Streptococcus’, ‘Hepatitis C’, ‘Human Papillomavirus’, ‘Influenza’,
‘Melanoma’, ‘Multiple Sclerosis’, ‘Neisseria Gonorrhea’, ‘Rheumatoid Arthritis’, and
‘Rotavirus’.
In an ideal situation, a decision like this would involve actual representatives from
various organizations who could assess each other, the criteria, and the vaccine candidates with
respect to the criteria. First, each decision maker would rank all of the decision makers, including
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him or herself, in order of ability to prioritize vaccine candidates. For the ranking, the first
position would be for the decision maker with the most ability to prioritize vaccine candidates,
while the last position would be for the decision maker with the least ability to prioritize vaccine
candidates. If someone thought that two or more decision makers were equal in rank, they could
rank them in the same position. Before these rankings would occur, though, each decision maker
would have the opportunity to review the CV’s of the other decision makers to gain an
understanding of their experience with vaccine development.
After ranking the decision makers, each decision maker would then rank the criteria of
evaluation in order of importance for prioritizing vaccine candidates. For the ranking, the first
position would be for the criterion that the decision maker thinks is most important to consider
when prioritizing vaccine candidates, while the last position would be for the criterion that the
decision maker thinks is least important to consider when prioritizing vaccine candidates. If a
decision maker considered two or more criteria to be equal in performance, they could rank them
in the same position.
Lastly, in an ideal situation, the decision makers would rank the vaccine candidates in
order of preference for the qualitative criteria (“Target Population”, “Potential to Improve
Delivery Methods”, and “Reduces Challenges Relating to Cold Chain Requirements”). For these
rankings, the first position would be for the vaccine candidate that the decision maker thought
best satisfied the criterion, while the last position would be for the vaccine candidate that the
decision maker though least satisfied the criterion. If a decision maker felt that two or more
vaccine candidates were equal in satisfying a certain criterion, they could rank them in the same
position.

19

Given that this is a derived experiment, assumptions were made about how the decision
makers might assess each other, the criteria, and the vaccine candidates with respect to the
qualitative criteria. The rankings that were created for each decision maker were used to generate
the pairwise comparison matrices for the model. The pairwise comparison matrices were created
according to the following rules: 1)

is an integer valued 1-10, 2)

= 1/

, 3)

= 1 for all i,

3) if the rank of option i, ( ), and the rank of option j, ( ), are equal, then elements
equal one, 4) if

and

> , then aij equals ( – + 1).

Typically, decision makers would create pairwise comparison matrices themselves rather
than record rankings of the decision makers, criteria, and alternatives, but constructing pairwise
comparison matrices is a cumbersome task for decision makers when more than a few criteria are
considered. In the case where actual decision makers would be using this model, it was decided
that it would be easier for decision makers to rank their preferences so pairwise comparison
matrices could be generated from those rankings.
For a quantitative criterion, alternatives are ranked according to how they perform with
respect to that criterion. For the quantitative criteria “QALYs Gained”, “Savings of Vaccine
Use”, “Incident Cases Prevented Per Year”, and “Premature Deaths Averted Per Year”, the
vaccine candidates were ranked in descending order. For the quantitative criteria “Time to
Licensure”, “Total Development Costs”, and “Cost-Effectiveness”, the vaccine candidates were
ranked in ascending order. The resulting rankings were then used to generate the appropriate
pairwise comparison matrices for all of the decision makers. Table 12 shows the values
associated with each vaccine initiative for the seven quantitative criteria.
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Table 12: Vaccine Example Quantitative Data
Incident Cases

Development

Premature

CostPrevented Per

Costs

QALYs

Savings of

Time to

Gained

Vaccine Use

Licensure

Deaths Averted

Effectiveness
Year

(millions)

Per Year

Chlamydia

-$350

101,000,000e

$360

4,373a

110,000

$175 million

15

Hepatitis C

$3,000

4,000,000f

$360

69,027a

41,000

$67.9 million

15

Human Papillomavirus

$4,000

22,389,339i

$360

276,961a

48,000

$140 million

7

Influenza

-$4,000

1,209,024,324i

$360

500,000b

125,000

$1 billion

7

Melanoma

$800

220,000g

$360

77,496a

14,000

$36.1 million

7

-$12,000

179,114i

$360

17,084a

15,000

$180 million

15

Neisseria Gonorrhea

$2,300

62,000,000h

$360

299a

47,000

$92.1 million

15

Rheumatoid Arthritis

-$4,000

1,455,307i

$360

37,670a

60,000

$300 million

15

Rotavirus

$30,000

78,362,687i

$120

527,000c

14,000

$120 million

3

$14,000

89,893,197i

$400

517,000d

6,200

$185 million

15

Multiple Sclerosis

Group A
Streptococcus
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Note. Data for ‘Cost-Effectiveness’, ‘Development Costs’, ‘QALYs Gained’, ‘Savings of Vaccine Use’, and ‘Time to Licensure’ from
“Vaccines for the 21st Century” [6].
a. "Global Health Observatory Data Repository." Cause-specific Mortality, 2008: WHO Region by Country. N.p., n.d. Web.
<http://apps.who.int/gho/data/node.main.887?lang=en>.
b. "Influenza (Seasonal)." WHO. N.p., n.d. Web. <http://www.who.int/mediacentre/factsheets/fs211/en/>.
c. Parashar, Umesh D., et al. "Global mortality associated with rotavirus disease among children in 2004." Journal of Infectious
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Table 13 shows the weight assigned to each decision maker as determined by the linear
programming model in (6).
Table 13: Vaccine Example Decision Maker Weights
Decision Maker

Weight

Public Health Unit
Representative

0.247393

Health Agency Representative

0.217927

Vaccine Industry Representative

0.1999291

International Vaccine Initiative
Representative

0.19927

Biopharmaceutical Industry
Representative

0.190454

Table 14 shows the weight assigned to each criterion as determined by the linear
programming model in (8).
Table 14: Vaccine Example Criterion Weights
Criterion

Weight

Prevented Deaths

0.154938

Incident Cases

0.138406

Cost Effectiveness

0.124149

Cold Chain

0.113343

QALYs Gained

0.111973

Development Costs

0.108845

Savings

0.103035
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Time to Licensure

0.0862401

Delivery Methods

0.0726194

Priority Population

0.0552014

Table 15 shows the ranking of vaccine candidates produced by the linear programming
model in (10).
Table 15: Model Vaccine Candidate Ranking
Vaccine Initiative

Weight

Influenza

0.2199

Rotavirus

0.1484

Chlamydia

0.1293

Group A Strep

0.106

HPV

0.1032

Arthritis

0.097

Hepatitis C

0.09299

Multiple Sclerosis

0.08339

Melanoma

0.06271

Gonorrhea

0.05956

The ranking suggests that the top three vaccine candidates are ‘Influenza’, ‘Rotavirus’,
and ‘Chlamydia’. This ranking is consistent with the quantitative data associated with these
vaccine candidates and the rankings provided by the decision makers.
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Lastly, the k-means clustering algorithm [17] was used to sort the vaccine candidates into
clusters and identify which vaccine candidates are similar in overall performance with respect to
the final ranking. Tables 16 through 19 show the clusters that result from applying the k-means
algorithm with k = 2 to k = 5.
Table 16: Vaccine Example k-means Clustering: k=2
Vaccine Initiative

Weight

Influenza

0.2199

Rotavirus

0.1484

Chlamydia

0.1293

Group A Strep

0.106

HPV

0.1032

Arthritis

0.097

Hepatitis C

0.09299

Multiple Sclerosis

0.08339

Melanoma

0.06271

Gonorrhea

0.05956
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Table 17: Vaccine Example k-means Clustering: k=3
Vaccine Initiative

Weight

Influenza

0.2199

Rotavirus

0.1484

Chlamydia

0.1293

Group A Strep

0.106

HPV

0.1032

Arthritis

0.097

Hepatitis C

0.09299

Multiple Sclerosis

0.08339

Melanoma

0.06271

Gonorrhea

0.05956

Table 18: Vaccine Example k-means Clustering: k=4
Vaccine Initiative

Weight

Influenza

0.2199

Rotavirus

0.1484

Chlamydia

0.1293

Group A Strep

0.106

HPV

0.1032

Arthritis

0.097

Hepatitis C

0.09299

Multiple Sclerosis

0.08339
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Melanoma

0.06271

Gonorrhea

0.05956

Table 19: Vaccine Example k-means clustering: k=5
Vaccine Initiative

Weight

Influenza

0.2199

Rotavirus

0.1484

Chlamydia

0.1293

Group A Strep

0.106

HPV

0.1032

Arthritis

0.097

Hepatitis C

0.09299

Multiple Sclerosis

0.08339

Melanoma

0.06271

Gonorrhea

0.05956

Sorting vaccine candidates into clusters is consistent with the idea that there is not
enough precision to decisively state that one vaccine candidate is better than another. For this
reason, vaccine candidates should be sorted into groups of similar performance, similar to how
hotels are grouped according to star ratings or countries are grouped according to credit ratings.
Review of the clusters can be used to identify where significant and insignificant differences
exist among vaccine candidates. For instance, the clustering of the vaccine candidates above
suggests that there is not a significant difference between the rankings of ‘Chlamydia’ and
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‘Rotavirus’, but there is a significant difference between the rankings of these two vaccine
candidates and ‘Influenza’.

5. Sensitivity Analysis
The goal of sensitivity analysis is to understand how changes in a problem’s parameters
affect the problem’s solution. In the case of the vaccine prioritization problem, it is important to
understand how changes in the decision maker’s preferences might affect the final ranking of
alternatives. Consider the objective function of model (6):

=∑

∑

For this problem, it is important to know how a decision maker’s assessment of his/her
fellow decision makers can change without affecting the final ranking of alternatives. Using
sensitivity analysis, the objective function coefficient ranges were determined; within these
ranges, the current basis remains optimal. For this problem, that provides the range of ∑
for each

. This range must be divided by h to determine how the summation of the decision

makers’ assessments (∑

) can vary when comparing decision maker to decision maker .

Table 12 shows the range in which ∑

can vary for each , .
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Table 12: Objective Function Coefficient Ranges
j = Health Agency

∑

Decision Makers

j = Public Health

∑

∑

j= Vaccine Industry

∑

∑

∑

i = Health Agency

Lower Bound
4.8725

Upper Bound
5.78

Lower Bound
-5.00E+100

Upper Bound
4.624

Lower Bound
6.675

Upper Bound
21.195

i = Public Health

5.415

6.685

-5.00E+100

5.57

7.925

32.235

i = Vaccine Industry

4.631

31.815

4.347

35.01

-5.00E+100

5.77

i = BiopharmIndustry

3.6505

44.575

3.4355

52.25

4.4285

5.00E+100

i = InternationalVacInit

4.427

5.19

4.6505

26.7

6.605

24.77

Table 12: Objective Function Coefficient Ranges (cont.)
j = BiopharmIndustry
Decision Makers

∑

j = InternationalVacInit

∑

∑

∑

i = Health Agency

Lower Bound
7.415

Upper Bound
21.555

Lower Bound
5.67

Upper Bound
23.9

i = Public Health

8.845

29.855

6.77

87.4

i = Vaccine Industry

5.64

8.19

5.11

45.865

-5.00E+100

5.64

3.993

68.65

7.365

21.33

-5.00E+100

5.625

i = BiopharmIndustry
i = InternationalVacInit

Although ∑

can vary within these ranges, the final ranking of alternatives can also change. Within the ranges shown in

Table 12, the values of the decision variables (

) remain unchanged, but the value of

may change, depending on whether the

variables associated with the coefficients are basic or nonbasic. If a variable is nonbasic, then the value of the
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coefficient can vary within the range shown in Table 12 and not affect the value of

or the final

ranking of alternatives. The ranges highlighted in Table 12 are associated with nonbasic
variables. For these ranges, the summation of the decision makers’ preferences can vary within
this range and not change the value of

or the final ranking of alternatives.

To understand how the final ranking of alternatives might also be affected by the weight of
the decision makers, sensitivity analysis was performed to determine how a single decision
maker’s weight can vary such that the ranking of a single vaccine candidate will remain the
same. As an example, the weight of ‘Health Agency Representative’ was analyzed to see how it
can vary such that the ranking of ‘Chlamydia’ will remain the same. A vaccine candidate’s
ranking will remain the same if the weight associated with it is greater than the weight of the
vaccine candidate ranked below it and less than the weight of the vaccine candidate ranked
above it. In this case, the weight of ‘Chlamydia’ must be greater than or equal to 0.1061 and less
than or equal to 0.1483 to remain the same.
To determine the range for which the weight of ‘Health Agency Representative’ can vary
such that the ranking of ‘Chlamydia’ will remain the same, equations 12 and 13 were solved.
∑

≤

(12)

∑

≥

(13)

The functions for each criterion (
(

) and for ‘Chlamydia’ with respect to each criterion

) were rewritten in terms of the values associated with those functions and
. Each equation was solved for

which represents the value that can be

added to or subtracted from the weight of ‘Health Agency Representative’ such that the ranking
of ‘Chlamydia’ will remain the same. The calculations associated with solving these equations
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can be found in Appendix K. The results of the analysis suggest that the weight of ‘Health
Agency Representative’ can vary between 0 and 0.321654 without affecting the final ranking of
‘Chlamydia’. A large range would suggest that ‘Health Agency Representative’ has little to no
influence over the ranking of ‘Chlamydia’, while a small range would suggest that ‘Health
Agency Representative’ has a significant influence over the ranking of ‘Chlamydia’. In this case,
‘Health Agency Representative’ has a small influence over the ranking of ‘Chlamydia’.

6. Conclusions
The Comprehensive DEA Methodology for Priority Determination in the Group AHP
(CDEAGAHP) does an effective job of calculating decision maker weights, criterion weights,
and weights for each project with respect to each criterion to come up with a final weight for
each project. The CDEAGAHP provides a methodology for calculating decision maker weights
using the members of the group in an anonymous manner which is essential to preserving the
integrity of the group decision making process. The methodology can be applied to any multiple
criteria decision making (MCDM) problem that involves multiple decision makers evaluating
multiple alternatives and assessing them according to a variety of quantitative and qualitative
criteria. Examples of MCDM problems the methodology can be applied to include choosing a
new vehicle for a company to purchase or identifying which vaccine candidates should receive
increased attention and funding around the world. The rankings generated by the model are
frequently consistent with the data related to the projects and the rankings provided by the
decision makers.
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Future work related to this problem includes evaluating alternative methods for incorporating
quantitative data into the model. Presently, quantitative data is gathered about each project with
respect to a particular criterion and the projects are ranked according to how they perform with
respect to that criterion. That ranking is then used to generate the pairwise comparison matrix for
all of the decision makers. Alternative methods could be used to incorporate this data.
For the vaccine prioritization problem specifically, testing the model with more decision
makers, criteria, and vaccine candidates will provide a better understanding of how the model
behaves when these conditions change. Additionally, collaboration with committee members of
the 2012 IOM model committee could provide insight to other aspects of the vaccine
prioritization problem which should be included in the model.
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Appendix A: Vehicle Experiment
The purpose of this experiment was to ensure that the DEA methodology for priority
determination in the group AHP can be extended to include the determination of decision maker
weights. This experiment serves as an illustrative example of the proposed methodology and
demonstrates how the methodology can be applied to other problems with multiple criteria and
decision makers. The methodology explained in Section 3.4 is used to calculate the weights of
the decision makers, criteria, and alternatives.
For the experiment, six groups of 5-9 individuals were asked to participate in a study that
involved ranking vehicle choices. Each person was told that they were an employee working for
a company that was considering the purchase of a vehicle for its sales team to use for business
trips. Each person was randomly assigned a role in the company and was given a packet of
information with eight vehicles to choose from. They were told that the company wanted to
include members from all levels of the organization, so the roles within the company included:
Chief Financial Officer, Human Resources Manager, Assembly Line Worker, Assembly Line
Supervisor, Sales Team Manager, and multiple Sales Team Representatives. In the packet of
information, the following information was provided about each vehicle: price, mileage, gas
mileage, body style, exterior color, features, and pictures of the exterior and interior of the car.
The eight vehicles were: a 2009 Ford F150 XLT, a 2013 Chrysler Town & Country Limited, a
2012 Jeep Grand Cherokee Laredo, a 2012 Toyota Camry SE, a 2002 Nissan Altima 2.5 S, a
2006 Dodge Grand Caravan SE, a 2012 Chevrolet Silverado 1500 LT, and a 2006 Honda CR-V
SE. Table 1 shows some of the characteristics for each vehicle.
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Table 1: Vehicle Characteristics
2009
Ford
F150
XLT

2013
Chrysler
Town &
Country
Limited

2012 Jeep
Grand
Cherokee
Laredo

2012
Toyota
Camry
SE

2002
Nissan
Altima
2.5 S

2006
Dodge
Grand
Caravan
SE

2012
Chevrolet
Silverado
1500 LT

2006
Honda
CR-V SE

Price

$17,994

$38,646

$25,991

$22,700

$5,995

$7,988

$27,869

$13,995

Mileage

49,832
mi.

12 mi.

29,288
mi.

7,658 mi.

97,176
mi.

60,500
mi.

7,225 mi.

85,000 mi.

Gas
Mileage

14-15
mpg
(city) / 18
-20 mpg
(highway)

17 mpg
(city) / 25
mpg
(highway)

19-20
mpg
(city) / 26
mpg
(highway)

12-15
mpg
(city) /
18-22
mpg
(highway)

21-23 mpg
(city) / 2629 mpg
(highway)

Pickup

Minivan

Minivan

Pickup

SUV

Body
Style

12-17
21-25
19-23
mpg
mpg
mpg
(city) /
(city) /
(city) /
18-23
30-35
26-29
mpg
mpg
mpg
(highway) (highway) (highway)
SUV

Sedan

Sedan

After reviewing the details about each car for a certain period of time, the individuals
were asked to, as a group, rank the vehicles in order of which they thought the company should
consider purchasing them. The individuals were informed that in addition to cost, the company
would like them to consider comfort, durability, and the impression the vehicle will make when
choosing which one to purchase. The first position in the ranking was for the vehicle the
company should give the most consideration to for purchasing, while the last position in the
ranking was for the vehicle the company should give the least consideration to for purchasing. If
the group decided that two or more vehicles were equal in rank, they were able to rank them in
the same position. Table 2 shows the resulting ranking for Group 1. The rankings for the rest of
the groups can be found in Appendix B.
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Table 2: Group 1 Vehicle Ranking
1) 2012 Toyota Camry SE
2) 2012 Jeep Grand Cherokee Laredo
3) 2006 Honda CR-V SE
4) 2002 Nissan Altima 2.5 S
5) 2006 Dodge Grand Caravan SE
6) 2013 Chrysler Town & Country Limited
7) 2012 Chevrolet Silverado 1500 LT, 2009 Ford F150 XLT

Following this activity, each member of the group was asked to independently fill out a
packet that had them rank the decision makers, criteria of evaluation, and vehicles in comparison
to the criteria. These rankings were requested to provide the information necessary to generate
the pairwise comparison matrices for the model.
First, each decision maker had to rank all of the decision makers, including him or
herself, in order of ability to choose a vehicle for the company to purchase. For the ranking, the
first position was for the decision maker with the most ability to choose a vehicle for the
company to purchase, while the ninth position was for the decision maker with the least ability to
choose a vehicle for the company to purchase. If someone thought that two or more decision
makers were equal in rank, they could rank them in the same position. Before the ranking, each
individual had to explain their experience with purchasing vehicles, so when they had to record
their ranking of decision makers, they had to consider an individual’s experience with purchasing
vehicles in addition to an individual’s position in the company.
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After ranking the decision makers, each person had to rank the criteria of evaluation in
order of importance in choosing a vehicle for the company to purchase. The criteria of evaluation
were: gas mileage, color, cost, body style, make, appearance, features, and mileage. For the
ranking, the first position was for the criterion that was most important to consider when
choosing a vehicle for the company to purchase, while the eighth position was for the criterion
that was least important to consider when choosing a vehicle for the company to purchase. If two
or more criteria were considered equal in importance, a decision maker could rank them in the
same position.
Lastly, the decision makers were asked to rank the vehicles in order of preference for the
qualitative criteria (color, body style, make, appearance, and features). For these rankings, the
first position was for the vehicle that the decision maker thought best satisfied that criterion,
while the eighth position was for the vehicle that the decision maker thought least satisfied that
criterion. If two or more vehicles were considered equal in satisfying a certain criterion, a
decision maker could rank them in the same position.
The rankings provided by each decision maker were used to generate the pairwise
comparison matrices for the model. Typically, decision makers would create pairwise
comparison matrices themselves rather than record rankings of the decision makers, criteria, and
alternatives, but constructing pairwise comparison matrices is a cumbersome task for decision
makers when more than a few criteria are considered. In an effort to provide decision makers
with an easy and quick method for identifying their preferences, the decision makers ranked their
preferences, (as described above), so pairwise comparison matrices could be generated later. The
pairwise comparison matrices were created according to the following rules: 1)

is an integer
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valued 1-9, 2)

= 1/

, 3)

, were equal, then element

= 1 for all i, 3) if the rank of option i, , and the rank of option j,
and

equaled one, 4) if

> , then aij equaled ( – + 1).

For the quantitative criteria ‘cost’ and ‘mileage’, the vehicles were ranked in ascending
order, and for the quantitative criteria ‘gas mileage’, the vehicles were ranked in descending
order. The resulting rankings were then used to generate the appropriate pairwise comparison
matrices using the method described above.
Table 3 shows the weight assigned to each decision maker for Group 1, as determined by
the model and the rankings provided by all of the decision makers. The weights assigned to each
decision maker for the rest of the groups can be found in Appendix C.
Table 3: Group 1 Decision Maker Weights
Decision Maker

Weight

Sales Team Representative

0.205

Sales Team Manager

0.161

Sales Team Representative

0.134

Assembly Line Supervisor

0.122

Assembly Line Worker

0.110

Sales Team Representative

0.103

Chief Financial Officer

0.100

Sales Team Representative

0.070

Human Resources Manager

0.049

When the decision makers were ranking the decision makers in the group, they were
considering an individual’s role within the company along with their experience with purchasing
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vehicles. This is evident by the resulting decision maker weights. In most cases, the individuals
with the most weight were a) part of the sales team, the group that would be using the new
vehicle, or b) the ones who seemed to have the most experience with vehicles based on the group
discussions. The individuals with the least weight seemed to have a lesser knowledge of vehicles
based on the group discussions, causing their peers to rank them low on their individual
assessments, regardless of their position in the company. This in turn resulted in them receiving
the least amount of influence in determining which vehicle the company should purchase.
Table 4 shows the weight assigned to each criterion for Group 1, as determined by the
rankings provided by all of the decision makers. The weights assigned to each criterion for the
rest of the groups can be found in Appendix D.
Table 4: Group 1 Criterion Weights
Criterion

Weight

Gas Mileage

0.235

Cost

0.185

Mileage

0.173

Body Style

0.158

Make

0.112

Features

0.106

Appearance

0.075

Color

0.037
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For most of the groups, ‘gas mileage’, ‘cost’, and ‘mileage’ were given higher
consideration to than the other criteria, while ‘color’, ‘features’, and ‘make’ were given less
consideration to than the other criteria.
Table 5 shows the ranking of vehicles produced by the model for Group 1. The ranking
of vehicles produced by the model for the rest of the groups can be found in Appendix E.
Table 5: Group 1 Model Vehicle Ranking
1) 2012 Toyota Camry SE
2) 2006 Honda CR-V SE
3) 2002 Nissan Altima 2.5 S
4) 2013 Chrysler Town & Country Limited
5) 2012 Jeep Grand Cherokee Laredo
6) 2006 Dodge Grand Caravan SE
7) 2012 Chevrolet Silverado 1500 LT
8) 2009 Ford F150 XLT

For most groups, a few differences existed between the ranking that resulted from the
model and the ranking that resulted from the group discussions. Changes in a vehicle’s ranking
occurred when the model needed to identify which vehicles performed best according to the
criteria that the decision makers determined to be significant. The ranking of the 2002 Nissan
Altima usually changed between the two rankings for this reason. For the group rankings,
decision makers would rank the Altima low due to its age and appearance. When it came to the
model ranking, though, decision makers frequently chose ‘cost’ and ‘gas mileage’ as top criteria.
Because the Altima is number one in terms of cost and number three in terms of gas mileage, it
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frequently moved up in rank between the group and model rankings. In these instances, the
model was simply accounting for the criteria that the decision makers determined to be
significant.
Lastly, the k-means clustering algorithm [16] was used to sort the vehicles into clusters
and identify which vehicles were similar in overall performance according to the final ranking.
Tables 6 through 9 show the clusters that result from applying the k-means algorithm to Group
1’s results with k = 2 to k = 5. The results of k-means clustering for the other groups can be
found in Appendices F-J.
Table 6: Group 1 K-means clustering: k = 2
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2006 Honda CR-V SE
2002 Nissan Altima 2.5 S
2013 Chrysler Town & Country Limited
2012 Jeep Grand Cherokee Laredo
2006 Dodge Grand Caravan SE
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT

Table 7: Group 1 K-means clustering: k = 3
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2006 Honda CR-V SE
2002 Nissan Altima 2.5 S
2013 Chrysler Town & Country Limited
2012 Jeep Grand Cherokee Laredo
2006 Dodge Grand Caravan SE
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT
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Table 8: Group 1 K-means clustering: k = 4
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2006 Honda CR-V SE
2002 Nissan Altima 2.5 S
2013 Chrysler Town & Country Limited
2012 Jeep Grand Cherokee Laredo
2006 Dodge Grand Caravan SE
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT

Table 9: Group 1 K-means clustering: k = 5
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2006 Honda CR-V SE
2002 Nissan Altima 2.5 S
2013 Chrysler Town & Country Limited
2012 Jeep Grand Cherokee Laredo
2006 Dodge Grand Caravan SE
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT

The clustering of the Group 1 vehicles shows that there is not a significant difference
between the ranking of the 2006 Honda CR-V and 2002 Nissan Altima, but there is a significant
difference between the ranking of these two vehicles and the 2012 Toyota Camry SE.
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Appendix B: Vehicle Example Group Vehicle Rankings
Table B1: Group 2 Vehicle Ranking
1) 2012 Toyota Camry SE
2) 2012 Jeep Grand Cherokee Laredo
3) 2013 Chrysler Town & Country Limited
4) 2006 Honda CR-V SE, 2006 Dodge Grand Caravan SE
5) 2012 Chevrolet Silverado 1500 LT
6) 2002 Nissan Altima 2.5 S
7) 2009 Ford F150 XLT

Table B2: Group 3 Vehicle Ranking
1) 2012 Toyota Camry SE
2) 2006 Honda CR-V SE
3) 2006 Dodge Grand Caravan SE
4) 2013 Chrysler Town & Country Limited
5) 2012 Jeep Grand Cherokee Laredo
6) 2002 Nissan Altima 2.5 S
7) 2012 Chevrolet Silverado 1500 LT, 2009 Ford F150 XLT

Table B3: Group 4 Vehicle Ranking
1) 2012 Toyota Camry SE
2) 2012 Jeep Grand Cherokee Laredo
3) 2006 Honda CR-V SE
4) 2002 Nissan Altima 2.5 S
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5) 2006 Dodge Grand Caravan SE
6) 2013 Chrysler Town & Country Limited
7) 2009 Ford F150 XLT
8) 2012 Chevrolet Silverado 1500 LT

Table B4: Group 5 Vehicle Ranking
1) 2012 Toyota Camry SE
2) 2012 Jeep Grand Cherokee Laredo
3) 2006 Honda CR-V SE
4) 2006 Dodge Grand Caravan SE
5) 2002 Nissan Altima 2.5 S
6) 2013 Chrysler Town & Country Limited
7) 2012 Chevrolet Silverado 1500 LT
8) 2009 Ford F150 XLT

Table B5: Group 6 Vehicle Ranking
1) 2012 Toyota Camry SE
2) 2012 Jeep Grand Cherokee Laredo
3) 2013 Chrysler Town & Country Limited
4) 2006 Honda CR-V SE
5) 2002 Nissan Altima 2.5 S
6) 2006 Dodge Grand Caravan SE
7) 2012 Chevrolet Silverado 1500 LT, 2009 Ford F150 XLT
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Appendix C: Vehicle Example Decision Maker Weights
Table C1: Group 2 Decision Maker Weights
Decision Maker

Weight

Sales Team Representative

0.203857

Assembly Line Supervisor

0.178611

Sales Team Representative

0.147251

Sales Team Representative

0.139284

Human Resources Manager

0.137797

Sales Team Manager

0.105846

Sales Team Representative

0.0490293

Assembly Line Worker

0.0430622

Chief Financial Officer

0.0348999

Table C2: Group 3 Decision Maker Weights
Decision Maker

Weight

Chief Financial Officer

0.219524

Sales Team Representative

0.173396

Sales Team Representative

0.165258

Assembly Line Supervisor

0.122575

Human Resources Manager

0.119295

Sales Team Manager

0.108542

Assembly Line Worker

0.101119

Sales Team Representative

0.0881727
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Table C3: Group 4 Decision Maker Weights
Decision Maker

Weight

Sales Team Manager

0.166367

Chief Financial Officer

0.164945

Human Resources Manager

0.160456

Sales Team Representative

0.13028

Sales Team Representative

0.12123

Sales Team Representative

0.118721

Sales Team Representative

0.113491

Assembly Line Supervisor

0.113004

Assembly Line Worker

0.0497484

Table C4: Group 5 Decision Maker Weights
Decision Maker

Weight

Sales Team Manager

0.288403

Chief Financial Officer

0.192078

Human Resources Manager

0.150424

Sales Team Representative

0.134789

Sales Team Representative

0.121699

Sales Team Representative

0.107403

Assembly Line Supervisor

0.0461601

Assembly Line Worker

0.0315077
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Table C5: Group 6 Decision Maker Weights
Decision Maker

Weight

Chief Financial Officer

0.319642

Sales Team Representative

0.281548

Sales Team Manager

0.200677

Sales Team Representative

0.191439

Human Resources Manager

0.0945378
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Appendix D: Vehicle Example Criterion Weights
Table D1: Group 2 Criterion Weights
Criterion

Weight

Mileage

0.211369

Cost

0.206324

Appearance

0.16657

Gas Mileage

0.153486

Body Style

0.114927

Make

0.0996222

Features

0.0741825

Color

0.0687389

Table D2: Group 3 Criterion Weights
Criterion

Weight

Cost

0.211628

Gas Mileage

0.193846

Mileage

0.181939

Appearance

0.125923

Body Style

0.125665

Make

0.0947138

Features

0.0880294

Color

0.0545618
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Table D3: Group 4 Criterion Weights
Criterion

Weight

Appearance

0.225753

Cost

0.214722

Gas Mileage

0.185236

Mileage

0.176551

Body Style

0.157368

Features

0.0885038

Make

0.0627282

Color

0.0287769

Table D4: Group 5 Criterion Weights
Criterion

Weight

Gas Mileage

0.235707

Mileage

0.205662

Cost

0.203233

Appearance

0.154181

Body Style

0.0982986

Features

0.0919879

Make

0.057545

Color

0.0251336
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Table D5: Group 6 Criterion Weights
Criterion

Weight

Body Style

0.261357

Mileage

0.202141

Appearance

0.173748

Gas Mileage

0.159869

Cost

0.102853

Make

0.0711132

Color

0.0506744

Features

0.0374448
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Appendix E: Vehicle Example Model Vehicle Ranking
Table E1: Group 2 Model Vehicle Ranking
Vehicle

Weight

1) Toyota

0.21226

2) Jeep

0.162489

3) Nissan

0.1478

4) Chrysler

0.145391

5) Honda

0.137473

6) Chevy

0.125838

7) Dodge

0.116254

8) Ford

0.0961831

Table E2: Group 3 Model Vehicle Ranking
Vehicle

Weight

1) Toyota

0.234231

2) Nissan

0.167109

3) Honda

0.159574

4) Chrysler

0.147843

5) Dodge

0.138073

6) Jeep

0.117067

7) Chevy

0.102084

8) Ford

0.0865146
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Table E3: Group 4 Model Vehicle Ranking
Vehicle

Weight

1) Toyota

0.233732

2) Nissan

0.176567

3) Jeep

0.16396

4) Chrysler

0.158372

5) Honda

0.157053

6) Chevy

0.120783

7) Dodge

0.117781

8) Ford

0.0891504

Table E4: Group 5 Model Vehicle Ranking
Vehicle

Weight

1) Toyota

0.241221

2) Nissan

0.161906

3) Honda

0.149379

4) Chrysler

0.139058

5) Jeep

0.126731

6) Dodge

0.114109

7) Chevy

0.110166

8) Ford

0.0876489
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Table E5: Group 6 Model Vehicle Ranking
Vehicle

Weight

1) Toyota

0.220474

2) Nissan

0.152795

3) Jeep

0.148616

4) Chrysler

0.136919

5) Honda

0.136383

6) Chevy

0.135783

7) Dodge

0.0940066

8) Ford

0.0933311
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Appendix F: Vehicle Example Group 2 k-means Clustering
Table F1: Group 2 K-means clustering: k = 2
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2012 Jeep Grand Cherokee Laredo
2002 Nissan Altima 2.5 S
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT

Table F2: Group 2 K-means clustering: k = 3
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2012 Jeep Grand Cherokee Laredo
2002 Nissan Altima 2.5 S
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT

Table F3: Group 2 K-means clustering: k = 4
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2012 Jeep Grand Cherokee Laredo
2002 Nissan Altima 2.5 S
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT
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Table F4: Group 2 K-means clustering: k = 5
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2012 Jeep Grand Cherokee Laredo
2002 Nissan Altima 2.5 S
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT
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Appendix G: Vehicle Example Group 3 k-means Clustering
Table G1: Group 3 K-means clustering: k = 2
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2006 Honda CR-V SE
2013 Chrysler Town & Country Limited
2006 Dodge Grand Caravan SE
2012 Jeep Grand Cherokee Laredo
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT

Table G2: Group 3 K-means clustering: k = 3
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2006 Honda CR-V SE
2013 Chrysler Town & Country Limited
2006 Dodge Grand Caravan SE
2012 Jeep Grand Cherokee Laredo
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT

Table G3: Group 3 K-means clustering: k = 4
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2006 Honda CR-V SE
2013 Chrysler Town & Country Limited
2006 Dodge Grand Caravan SE
2012 Jeep Grand Cherokee Laredo
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT
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Table G4: Group 3 K-means clustering: k = 5
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2006 Honda CR-V SE
2013 Chrysler Town & Country Limited
2006 Dodge Grand Caravan SE
2012 Jeep Grand Cherokee Laredo
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT
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Appendix H: Vehicle Example Group 4 k-means Clustering
Table H1: Group 4 K-means clustering: k = 2
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2012 Jeep Grand Cherokee Laredo
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT

Table H2: Group 4 K-means clustering: k = 3
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2012 Jeep Grand Cherokee Laredo
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT

Table H3: Group 4 K-means clustering: k = 4
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2012 Jeep Grand Cherokee Laredo
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT
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Table H4: Group 4 K-means clustering: k = 5
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2012 Jeep Grand Cherokee Laredo
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT
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Appendix I: Vehicle Example Group 5 k-means Clustering
Table I1: Group 5 K-means clustering: k = 2
9) 2012 Toyota Camry SE
10) 2002 Nissan Altima 2.5 S
11) 2006 Honda CR-V SE
12) 2013 Chrysler Town & Country Limited
13) 2012 Jeep Grand Cherokee Laredo
14) 2006 Dodge Grand Caravan SE
15) 2012 Chevrolet Silverado 1500 LT
16) 2009 Ford F150 XLT

Table I2: Group 5 K-means clustering: k = 3
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2006 Honda CR-V SE
2013 Chrysler Town & Country Limited
2012 Jeep Grand Cherokee Laredo
2006 Dodge Grand Caravan SE
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT

Table I3: Group 5 K-means clustering: k = 4
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2006 Honda CR-V SE
2013 Chrysler Town & Country Limited
2012 Jeep Grand Cherokee Laredo
2006 Dodge Grand Caravan SE
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT
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Table I4: Group 5 K-means clustering: k = 5
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2006 Honda CR-V SE
2013 Chrysler Town & Country Limited
2012 Jeep Grand Cherokee Laredo
2006 Dodge Grand Caravan SE
2012 Chevrolet Silverado 1500 LT
2009 Ford F150 XLT
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Appendix J: Vehicle Example Group 6 k-means Clustering
Table J1: Group 6 K-means clustering: k = 2
17) 2012 Toyota Camry SE
18) 2002 Nissan Altima 2.5 S
19) 2012 Jeep Grand Cherokee Laredo
20) 2013 Chrysler Town & Country Limited
21) 2006 Honda CR-V SE
22) 2012 Chevrolet Silverado 1500 LT
23) 2006 Dodge Grand Caravan SE
24) 2009 Ford F150 XLT

Table J2: Group 6 K-means clustering: k = 3
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2012 Jeep Grand Cherokee Laredo
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT

Table J3: Group 6 K-means clustering: k = 4
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2012 Jeep Grand Cherokee Laredo
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT
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Table J4: Group 6 K-means clustering: k = 5
1)
2)
3)
4)
5)
6)
7)
8)

2012 Toyota Camry SE
2002 Nissan Altima 2.5 S
2012 Jeep Grand Cherokee Laredo
2013 Chrysler Town & Country Limited
2006 Honda CR-V SE
2012 Chevrolet Silverado 1500 LT
2006 Dodge Grand Caravan SE
2009 Ford F150 XLT
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Appendix K: Sensitivity Analysis Calculation

Final weight of Alternative

= ∑

= 0.1293
0.1061 ≤

≤ 0.1483

≥(

) +
)+
)+(

(
(
+(
(
(
(

)
(

)+(

)+

)+
)+
+(

0.1483 ≥
(0.174248776 +

(0.20745582))(0.094918693 +

(0.100617054 +

(0.120296914))(0.105894635 +

(0.08376367)) +

(0.027392656 +

(0.038151967))(0.052969646 +

(0.09016668)) +

(0.17421749 +

(0.20829227))(0.120315309 +

(0.052596999 +

(0.062884365))(0.076275375 +

(0.075880705 +

(0.0907221))(0.09001065 +

(0.08642504)) +

(0.01922052))(0.136847309 +

(0.08301262)) +

(0.01607623 +

(0.08454348)) +

(0.08301262)) +
(0.04572506)) +

(0.052125907 +

(0.054869718))(0.049243159 +

(0.02734054)) +

(0.173912778 +

(0.207928445))(0.093882309 +

(0.08301262)) +

(0.064371765 +

(0.076962172))(0.084057963 +

(0.08707979))
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0.1483 ≥
0.0165394661 + (0.0147315979)
2
(0.017539037)
+

+ (0.0196914353)

+

0.0106548062 + (0.0084280537)
2
(0.010076511)
+

+ (0.0127387978)

+

0.0014509793 + (0.0024699048)
2
(0.0034400362)
+

+ (0.0020208962)

+

0.0209610311 + (0.0144622503)
2
(0.0172908871
+

+ (0.0250607488)

+

0.0040118558 + (0.0024050009)
2
(0.0028753914)
+

+ (0.0047965285)

+

0.0068300716 + (0.006557993)
(0.0078406611)

+ (0.0081659552)
2

0.0021999888 + (0.00133453)
(0.0015955457)

+

+
+ (0.0026302764)

2

+

+

0.0025668443 + (0.0014251504)
2
(0.0015001677)
+

+ (0.0027019582)

+

0.0163273332 + (0.0144369554)
2
(0.017260685)
+

+ (0.0195208025)

+

0.0054109594 + (0.0056054798)
2
(0.0067018498)

+ (0.0064692834)

+

0.1483 ≥ 0.0869533358 + (0.0718569162)
2
(0.086120772)

+ (0.1037966823)

0.1483 ≥ 0.0869533358 + (0.1756535985)

+ (0.086120772)

(0.086120772)

2

+ (0.1756535985)

+

2

– 0.0613466642 ≤ 0

= -2.343571315, 0.3039519014
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0.1061 ≤ 0.0869533358 + (0.1756535985)
2

(0.086120772)

+ (0.1756535985)

+ (0.086120772)

2

– 0.0191466642 ≥ 0

= -2.1433466462, 0.1037272324

= 0.217927
0.217927 – 2.34357 < xHA < 0.217927 + 0.103727
0<

< 0.321654
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